{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:21:24Z","timestamp":1774585284658,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13300-024-01573-y","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T03:35:31Z","timestamp":1713929731000},"page":"1473-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exogenous Insulin Antibody Syndrome (EIAS) Presenting in an Elderly, Long-Term Patient with Type\u00a01\u00a0Diabetes\u00a0Mellitus that Resolved with Low-Cost Outpatient Therapy with Mycophenolate Mofetil and Regular Insulin by Pump"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5241-3797","authenticated-orcid":false,"given":"Terri","family":"Jerkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Stockham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S. H.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"1573_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13098-021-00658-z","volume":"13","author":"Z Li","year":"2021","unstructured":"Li Z, Yi D, Zheng L, et\u00a0al. Analysis of the clinical characteristics of insulin autoimmune syndrome induced by exogenous insulin in diabetic patients. Diabetol Metab Syndr. 2021;13:38. https:\/\/doi.org\/10.1186\/s13098-021-00658-z.","journal-title":"Diabetol Metab Syndr"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/EC-17-0309","volume":"7","author":"S Hu","year":"2018","unstructured":"Hu S, Chen F. Exogenous insulin antibody syndrome (EIAS); a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients. Endocr Connect. 2018;7:R47\u201355. https:\/\/doi.org\/10.1530\/EC-17-0309.","journal-title":"Endocr Connect"},{"issue":"10","key":"1573_CR3","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1210\/jc.2018-00972","volume":"103","author":"D Church","year":"2018","unstructured":"Church D, Cardoso L, Kay RG, Williams CL, et\u00a0al. Assessment and management of anti-insulin autoantibodies in varying presentations of insulin autoimmune syndrome. JCEM. 2018;103(10):3845\u201355. https:\/\/doi.org\/10.1210\/jc.2018-00972.","journal-title":"JCEM"},{"issue":"10","key":"1573_CR4","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s13300-021-01129-4","volume":"12","author":"T Jerkins","year":"2021","unstructured":"Jerkins T, Bell DSH. Development of exogenous insulin antibody syndrome in a patient with newly diagnosed type 1 diabetes successfully treated with oral immunosuppressive monotherapy. Diabetes Ther. 2021;12(10):2795\u20139. https:\/\/doi.org\/10.1007\/s13300-021-01129-4. (Epub 2021 Aug 17).","journal-title":"Diabetes Ther."},{"issue":"Supplement 1","key":"1573_CR5","doi-asserted-by":"publisher","first-page":"149-LB","DOI":"10.2337\/db22-149-LB","volume":"71","author":"L Saba","year":"2022","unstructured":"Saba L, Orandi AB, Pittock S, et\u00a0al. 149-LB: pediatric exogenous insulin antibody syndrome\u2014Successful treatment with mycophenolate mofetil. Diabetes. 2022;71(Supplement 1):149-LB. https:\/\/doi.org\/10.2337\/db22-149-LB.","journal-title":"Diabetes"},{"key":"1573_CR6","doi-asserted-by":"publisher","DOI":"10.1159\/000531767","author":"L Saba","year":"2023","unstructured":"Saba L, Fatica E, Orandi A, Pittock S. Exogenous insulin antibody syndrome in a pediatric patient: successful treatment with mycophenolate mofetil. Horm Res Pediatr. 2023. https:\/\/doi.org\/10.1159\/000531767.","journal-title":"Horm Res Pediatr."},{"key":"1573_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101783","volume":"56","author":"R Chang","year":"2023","unstructured":"Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ. Risk of autoimmune diseases in patients with COVID-19: a\u00a0retrospective cohort study. EClinicalMedicine. 2023;56: 101783. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101783. (Epub 2023 Jan 10).","journal-title":"EClinicalMedicine."},{"issue":"2","key":"1573_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155\u201362. https:\/\/doi.org\/10.1097\/BOR.0000000000000776.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"1573_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, Pan HF. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386\u2013401. https:\/\/doi.org\/10.1111\/imm.13443. (Epub 2022 Jan 7).","journal-title":"Immunology"},{"issue":"23","key":"1573_CR10","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.2023.8674","volume":"329","author":"A Weiss","year":"2023","unstructured":"Weiss A, Donnachie E, Beyerlain A. Type 1 diabetes incidence and risk in children with a diagnosis of Covid-19. JAMA. 2023;329(23):2089\u201391. https:\/\/doi.org\/10.1001\/jama.2023.8674.","journal-title":"JAMA"},{"issue":"6","key":"1573_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/\/jamanetworkopen.2023.21231","volume":"6","author":"K Clemens","year":"2023","unstructured":"Clemens K, Holl RW, Rosenbauer J. Elucidating the underlying mechanisms of the marked increase in childhood type1 diabetes during the Covid-19 pandemic\u2014The diabetes pandemic. JAMA Netw Open. 2023;6(6): e2321231. https:\/\/doi.org\/10.1001\/\/jamanetworkopen.2023.21231.","journal-title":"JAMA Netw Open"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.15585\/mmwr.mm7102e2","volume":"71","author":"CE Barrett","year":"2022","unstructured":"Barrett CE, Koyana AK, Alvarez P, et\u00a0al. Risk for newly diagnosed diabetes > 30 days after Sars-CoV-2 infections among persons <18 years\u2014United States March 1, 202\u2013June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59\u201365.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/DMSO.S219438","volume":"13","author":"D Cappellani","year":"2020","unstructured":"Cappellani D, Macchia E, Falorni A, Marchetti P. Insulin autoimmune syndrome (Hirata disease): a comprehensive review fifty years after its first description. Diabetes Metab Syndr Obes. 2020;13:963\u201378. https:\/\/doi.org\/10.2147\/DMSO.S219438.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"1573_CR14","first-page":"312","volume":"13","author":"Y Hirata","year":"1970","unstructured":"Hirata Y, Ishizu H, Ouchi N. Insulin autoimmunity in a case of spontaneous hypoglycemia. J Jpn Diabetes Soc. 1970;13(3):312\u201320.","journal-title":"J Jpn Diabetes Soc."},{"issue":"11","key":"1573_CR15","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1515\/cclin-2015-1255T","volume":"54","author":"AA Ismail","year":"2016","unstructured":"Ismail AA. The insulin autoantibody syndrome (IAS) as a cause of hypoglycemia: an update of pathophysiology biochemical investigations and diagnosis. Clin Chem Lab Med. 2016;54(11):1715\u201324. https:\/\/doi.org\/10.1515\/cclin-2015-1255T.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"1573_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0168.8227(90)90063-y","volume":"10","author":"S Takayama-Hasumi","year":"1990","unstructured":"Takayama-Hasumi S, Eguchi Y, Sato A, et\u00a0al. Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan. Diabetes Res Clin Pract. 1990;10(3):211\u20134. https:\/\/doi.org\/10.1016\/0168.8227(90)90063-y.","journal-title":"Diabetes Res Clin Pract"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2147\/DMSO.S4004222","volume":"16","author":"K-F Hua","year":"2023","unstructured":"Hua K-F, Jing B-Y, Wu Y-H. The application of the insulin to c-peptide molar ratio in primary screening for insulin antibodies in type 2 diabetes mellitus patients: a further quantitative study on the relationship between ICPR and insulin antibodies. Diabetes Metab Syndr Obes. 2023;16:1121\u201332. https:\/\/doi.org\/10.2147\/DMSO.S4004222.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1573_CR18","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.diabres.2008.10.015","volume":"83","author":"ZY Uchigata","year":"2009","unstructured":"Uchigata ZY, Hirata Y, Iwamoto Y. Drug induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83(1):e19\u201320.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1573_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/50140-6736(83)91031-0","volume":"81","author":"Y Hirata","year":"1974","unstructured":"Hirata Y. Methimazole and insulin autoimmune with hypoglycemia in Grave\u2019s disease. Ann Inter Med. 1974;81(2):214\u20138. https:\/\/doi.org\/10.1016\/50140-6736(83)91031-0.","journal-title":"Ann Inter Med"},{"issue":"5","key":"1573_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2969\/internalmedicine.46.1893","volume":"46","author":"Y Takeuchi","year":"2007","unstructured":"Takeuchi Y, Miyamoto T, Kakizawa T, et\u00a0al. Insulin autoimmune syndrome possibly caused by alpha lipoic acid. Intern Med. 2007;46(5):237\u20139. https:\/\/doi.org\/10.2969\/internalmedicine.46.1893.","journal-title":"Intern Med"},{"issue":"9","key":"1573_CR21","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/j.clinthera.2023.06.026","volume":"45","author":"FI Corona-Meraz","year":"2023","unstructured":"Corona-Meraz FI, Quintero-Castillo BP, Henandez-Palm LA, et\u00a0al. Long covid-19 and insulin autoimmune syndrome: a case report. Clin Ther. 2023;45(9):e187\u201392. https:\/\/doi.org\/10.1016\/j.clinthera.2023.06.026. (Epub 2023 Jul 29).","journal-title":"Clin Ther"},{"issue":"1","key":"1573_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/ijemcr.ijemcr_3_22","volume":"1","author":"MK Sehemby","year":"2023","unstructured":"Sehemby MK, Lila AR, Sarathi V, Bandgar T. Insulin autoimmune hypoglycemia syndrome following coronavirus disease 2019 infection. Indian J Endocrinol Metab Case Rep. 2023;1(1):5\u20138. https:\/\/doi.org\/10.4103\/ijemcr.ijemcr_3_22.","journal-title":"Indian J Endocrinol Metab Case Rep"},{"issue":"12 supplement","key":"1573_CR23","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/j.eprac.2023.10.032","volume":"29","author":"M Alabbood","year":"2023","unstructured":"Alabbood M, Chamberlain M, Penner H. Abstract #1602427: Post-covid-19 autoimmune hypoglycemia: a case report. Endocr Pract. 2023;29(12 supplement):S145\u20136.","journal-title":"Endocr Pract"},{"issue":"1","key":"1573_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2337\/dc18-1157","volume":"42","author":"JW Hughes","year":"2019","unstructured":"Hughes JW, Bao YK, Salam M, Joshi P, et\u00a0al. Late-onset T1DM and older age predict risk of additional autoimmune disease. Diabetes Care. 2019;42(1):32\u20138. https:\/\/doi.org\/10.2337\/dc18-1157. (Epub 2018 Oct 25).","journal-title":"Diabetes Care"},{"issue":"4","key":"1573_CR25","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/dc10-1903","volume":"34","author":"D Tridgell","year":"2011","unstructured":"Tridgell D, Spiekerman C, Wang RS, Greenbaum CJ. Intersection of and duration in percent of GAD and IA-2 antibody-positive in the diabetes genetics consortium database. Diabetes Care. 2011;34(4):988\u201393. https:\/\/doi.org\/10.2337\/dc10-1903.","journal-title":"Diabetes Care"},{"issue":"Supplement 2","key":"1573_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2337\/diacare.5.2.S175","volume":"5","author":"F Maneschi","year":"1982","unstructured":"Maneschi F, Fineberg SE, Kohner EM. Successful treatment of immune-mediated insulin resistance by human insulin (recombinant DNA). Diabetes Care. 1982;5(Supplement 2):175\u20139. https:\/\/doi.org\/10.2337\/diacare.5.2.S175.","journal-title":"Diabetes Care"},{"key":"1573_CR27","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.diabres.2011.04.001","volume":"94","author":"A Otoh","year":"2011","unstructured":"Otoh A, Saisho Y, Mitsuishi M, et\u00a0al. Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody\u2014A case report. Diabetes Res Clin Pract. 2011;94:e53\u20134. https:\/\/doi.org\/10.1016\/j.diabres.2011.04.001. (discussion e55).","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl o081","key":"1573_CR28","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1191\/0961203305lu2109oa","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl o081):s2-8. https:\/\/doi.org\/10.1191\/0961203305lu2109oa.","journal-title":"Lupus"},{"issue":"4","key":"1573_CR29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/mr\/roab076","volume":"32","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Hashimoto H, Masumoto M. Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheumatol. 2022;32(4):746\u201354. https:\/\/doi.org\/10.1093\/mr\/roab076.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"1573_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ckj\/sfz061","volume":"13","author":"K Saravanakumar","year":"2019","unstructured":"Saravanakumar K, et\u00a0al. The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study. Clin Kidney J. 2019;13(2):179\u201383. https:\/\/doi.org\/10.1093\/ckj\/sfz061.","journal-title":"Clin Kidney J"},{"key":"1573_CR31","doi-asserted-by":"crossref","unstructured":"Eickenberg S, Mickholz E, Jung E, et\u00a0al. Arthritis Res Therapy. 2012;14:R110. http:\/\/arthritis-research.com\/content\/14\/3\/R110.","DOI":"10.1186\/ar3835"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01573-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:19:25Z","timestamp":1715768365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01573-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01573-y","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. David Bell is an editorial board member of Diabetes Therapy. Dr. Bell was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He has no other conflicts of interest to declare. Dr. Terri Jerkins has received funding from NovoNordisk, Corcept, and Bayer Pharmaceuticals as a speaker, and she has research funding from AbbVie, Crinetics, and NovoNordisk Pharmaceuticals. Dr. Katherine Stockham as no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent to publish was provided by the patient prior to the development and production of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}]}}